US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| NALMEFENE HYDROCHLORIDE | EQ 2MG BASE/2ML (EQ 1MG BASE/ML) | solution · intramuscular, intravenous, subcutaneous | KNOA PHARMA | Prescription | 8 Feb 2022 |
| OPVEE | EQ 2.7MG BASE/SPRAY | spray · nasal | INDIVIOR | Prescription | 22 May 2023 |
| NALMEFENE HYDROCHLORIDE | EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML); EQ 2MG BASE/2ML (EQ 1MG BASE/ML); 2MG BASE/2ML (EQ 1MGBASE/ML) | solution · intramuscular, intravenous, subcutaneous | CHENGDU SHUODE | Prescription | 15 Nov 2023 |
| ZURNAI (AUTOINJECTOR) | EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML) | solution · intramuscular, subcutaneous | KNOA PHARMA | Prescription | 7 Aug 2024 |
| REVEX | EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 2MG BASE/2ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · intramuscular, intravenous, subcutaneous | HIKMA PHARMS | Discontinued | 17 Apr 1995 |
EMA European Union — centrally authorised medicines
Selincro H. Lundbeck A/S · Authorised · authorised 24 Feb 2013 · ATC N07BB05
Therapeutic indication (EMA)
Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level (see section 5.1), without physical withdrawal symptoms and who do not require immediate detoxification. Selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Selincro should be initiated only in patients who continue to have a high drinking-risk level two weeks after initial assessment.
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | OPVEE 2.7 MG NASAL SPRAY | $46.78808 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Nalmefene 18mg tablets | £84.84 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.